ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

367
Analysis
Health Care • China
Shanghai Henlius Biotech is a global, innovation-driven biopharmaceutical company focused on delivering high-quality, affordable biologic therapies for oncology, autoimmune diseases, and ophthalmic diseases. The company is engaged in biopharmaceutical research and development, manufacturing, and commercialization, offering products such as the biosimilars HANLIKANG (rituximab), HANQUYOU (trastuzumab), HANDAYUAN (adalimumab), and HANBEITAI (bevacizumab), as well as the innovative biologic HANSIZHUANG (serplulimab). Headquartered in Shanghai, China, the company was founded in 2010.
more
•25 Feb 2025 01:01

Pentamaster International (1665 HK): A Deal Break Will Be the Right Result for a Light Offer

The share price action suggests a deal break, which would be a fair result for a light offer. It is best to steer clear, as verifying whether a...

Logo
867 Views
Share
•20 Feb 2025 11:54

CNBM (3323 HK): Whitewash Waiver Secured. Next Is The Proration

I'm inclined to simply short outright here, if I had guaranteed take-no-action borrow. Especially as the price closes in on the tender price, and...

Logo
879 Views
Share
bullish•PEC
•18 Feb 2025 10:18

PEC Ltd. (PEC SP): Privatisation Offer From Liberty Group

This is done. If small, illliquid arbs are your bent, and assuming late May payment, I'd pay up to S$0.79/share for a gross/annualised return of 6%...

Logo
844 Views
Share
•18 Feb 2025 08:37

Tam Jai (2217 HK): Toridoll (3397 JP)'s Excellent Offer

This is done. No competing Offer will emerge. If payment on or around mid-July, and small-cap arbs are your thing, I'd pay up to HK$1.49/share for...

Logo
1.1k Views
Share
bullish•Soundwill
•17 Feb 2025 10:48

Soundwill Holdings (878 HK): Privatisation Expected From The Controlling Family

Despite Soundwill's illiquidity, the controlling family probably still needs to offer a premium of 50%-75%. Not just to account for the low P/B...

Logo
827 Views
Share
x